Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to “Sell” at BidaskClub

BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong sell rating to a sell rating in a report issued on Friday morning, BidAskClub reports.

REGN has been the topic of several other research reports. TheStreet lowered Weis Markets from a b- rating to a c+ rating in a report on Wednesday, June 5th. Cowen reiterated a hold rating and set a $353.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 7th. Morgan Stanley reiterated an overweight rating and set a GBX 2,280 ($29.79) price target on shares of Anglo American in a report on Wednesday, May 8th. Leerink Swann set a $453.00 price target on Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, June 11th. Finally, Piper Jaffray Companies reiterated an overweight rating and set a $435.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 7th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of Hold and a consensus target price of $394.65.

NASDAQ REGN opened at $298.11 on Friday. Regeneron Pharmaceuticals has a 52 week low of $287.66 and a 52 week high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58. The business’s fifty day moving average is $306.59. The stock has a market cap of $32.58 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 1.40 and a beta of 1.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The company had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. During the same quarter in the prior year, the firm earned $4.67 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 18.37 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total value of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The disclosure for this sale can be found here. Insiders own 11.84% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.9% in the 1st quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock valued at $2,481,339,000 after buying an additional 113,683 shares during the period. FMR LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.6% in the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the period. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after buying an additional 78,143 shares during the period. American Century Companies Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.7% in the 1st quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after buying an additional 37,573 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 1st quarter. Northern Trust Corp now owns 972,988 shares of the biopharmaceutical company’s stock valued at $399,528,000 after buying an additional 20,218 shares during the period. 66.86% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Momentum Indicator: Relative Strength Index

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.